| abstract |
The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R<1> is C,-C6alkyl, Ci-C6alkoxyC,C3alkyl or C,-C6alkoxyC,-C6alkoxyC,-C3alkyl; R<2> is hydrogen or C,-C6alkyl; L is a three 5 atom linkage selected from -CH2-X-CH2- and -CH2-CH2-X- where the right hand side of the linkage is attached to R<3> and where X is oxygen, sulfur or methylene; R<3> is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C1-C6alkyl, halo, haloC,-C6alkyl, C,-C6alkoxy, haloC1-C6alkoxy, C1-C6alkylthio, haloC,-C6alkylthio and nitrile; and R<4> and R<5> are either both hydrogen, or one of R<4> and R<5> is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen. |